drugset / Trial / NCT05515796
Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors
Phase 2
Completed
189 enrolled
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Non-randomizedParallel-groupOpen-labelTreatment
Summary
immunotherapy，gastric cancer，rectal cancer，biomark
Timeline
- Start
- 2022-09-01
- Primary completion
- 2026-03-25
- Completion
- 2026-03-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Terelizumab | Unknown | 200 mg | — |
| Subject | Trastuzumab | Monoclonal antibody | 6 mg/kg | — |
| Background | Capecitabine | Small molecule | 1000 mg/m2 | — |
| Background | Oxaliplatin | Small molecule | 130 mg/m2 | — |